Bicycle Therapeutics plc Operating Cash Flow
Bicycle Therapeutics plc (BCYC) reported Operating Cash Flow of -$115.53 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-07-30
- Bicycle Therapeutics plc net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$49.61M.
- Bicycle Therapeutics plc net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$65.92M.
- Bicycle Therapeutics plc net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$19.35M.
- Bicycle Therapeutics plc net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$71.17M.
- Bicycle Therapeutics plc net cash provided by (used in) operating activities for fiscal 2025 was -$249.68M.
- Bicycle Therapeutics plc net cash provided by (used in) operating activities for fiscal 2024 was -$164.72M.
- Bicycle Therapeutics plc net cash provided by (used in) operating activities for fiscal 2023 was -$60.63M.
- Bicycle Therapeutics plc net cash provided by (used in) operating activities for fiscal 2022 was -$86.11M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$49.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$115.53M 10-Q · filed 2026-07-30 | -$134.88M derived: sum of 3 quarters · filed 2026-07-30 | -$206.05M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$65.92M 10-Q · filed 2026-04-30 | -$85.27M derived: sum of 2 quarters · filed 2026-04-30 | -$156.44M derived: sum of 3 quarters · filed 2026-04-30 | -$229.23M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | -$19.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$90.52M derived: sum of 2 quarters · filed 2026-03-17 | -$163.31M derived: sum of 3 quarters · filed 2026-07-30 | -$249.68M 10-K · filed 2026-03-17 |
| 2025-09-30 | -$71.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$143.96M derived: sum of 2 quarters · filed 2026-07-30 | -$230.33M 10-Q · filed 2025-10-30 | -$239.72M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$72.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$159.16M 10-Q · filed 2026-07-30 | -$168.55M derived: sum of 3 quarters · filed 2026-07-30 | -$208.38M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$86.37M 10-Q · filed 2026-04-30 | -$95.77M derived: sum of 2 quarters · filed 2026-04-30 | -$135.60M derived: sum of 3 quarters · filed 2026-04-30 | -$180.22M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$9.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$49.23M derived: sum of 2 quarters · filed 2026-03-17 | -$93.86M derived: sum of 3 quarters · filed 2026-03-17 | -$164.72M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$39.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$84.46M derived: sum of 2 quarters · filed 2025-10-30 | -$155.33M 10-Q · filed 2025-10-30 | -$202.62M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | -$44.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$115.50M 10-Q · filed 2025-08-08 | -$162.78M derived: sum of 3 quarters · filed 2026-03-17 | -$163.81M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | -$70.87M 10-Q · filed 2025-05-01 | -$118.16M derived: sum of 2 quarters · filed 2026-03-17 | -$119.18M derived: sum of 3 quarters · filed 2026-03-17 | -$85.09M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | -$47.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$48.31M derived: sum of 2 quarters · filed 2026-03-17 | -$14.22M derived: sum of 3 quarters · filed 2026-03-17 | -$60.63M 10-K · filed 2026-03-17 |
| 2023-09-30 | -$1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $33.07M derived: sum of 2 quarters · filed 2024-10-31 | -$13.34M 10-Q · filed 2024-10-31 | -$43.65M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $34.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$12.31M 10-Q · filed 2024-08-06 | -$42.62M derived: sum of 3 quarters · filed 2025-02-25 | -$48.49M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$46.41M 10-Q · filed 2024-05-02 | -$76.72M derived: sum of 2 quarters · filed 2025-02-25 | -$82.59M derived: sum of 3 quarters · filed 2025-02-25 | -$106.12M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$30.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$36.18M derived: sum of 2 quarters · filed 2025-02-25 | -$59.71M derived: sum of 3 quarters · filed 2025-02-25 | -$86.11M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$5.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$29.40M derived: sum of 2 quarters · filed 2023-11-02 | -$55.80M 10-Q · filed 2023-11-02 | -$66.24M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | -$23.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$49.93M 10-Q · filed 2023-08-03 | -$60.37M derived: sum of 3 quarters · filed 2024-02-20 | -$38.65M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | -$26.40M 10-Q · filed 2023-05-04 | -$36.84M derived: sum of 2 quarters · filed 2024-02-20 | -$15.12M derived: sum of 3 quarters · filed 2024-02-20 | -$27.49M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | -$10.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $11.28M derived: sum of 2 quarters · filed 2024-02-20 | -$1.09M derived: sum of 3 quarters · filed 2024-02-20 | -$14.79M 10-K · filed 2024-02-20 |
| 2021-09-30 | $21.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $9.35M derived: sum of 2 quarters · filed 2022-11-03 | -$4.36M 10-Q · filed 2022-11-03 | -$20.98M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$12.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$26.08M 10-Q · filed 2022-08-04 | -$42.69M derived: sum of 3 quarters · filed 2023-02-28 | -$52.68M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$13.71M 10-Q · filed 2022-05-05 | -$30.32M derived: sum of 2 quarters · filed 2023-02-28 | -$40.31M derived: sum of 3 quarters · filed 2023-02-28 | -$52.66M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$16.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$26.60M derived: sum of 2 quarters · filed 2023-02-28 | -$38.95M derived: sum of 3 quarters · filed 2023-02-28 | -$17.79M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$9.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$22.33M derived: sum of 2 quarters · filed 2021-11-04 | -$1.17M 10-Q · filed 2021-11-04 | -$6.09M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$12.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $8.81M 10-Q · filed 2021-08-05 | $3.89M derived: sum of 3 quarters · filed 2022-03-01 | -$6.99M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $21.16M 10-Q · filed 2021-05-06 | $16.24M derived: sum of 2 quarters · filed 2022-03-01 | $5.36M derived: sum of 3 quarters · filed 2022-03-01 | -$2.25M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$4.92M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$15.80M derived: sum of 2 quarters · filed 2022-03-01 | -$23.41M derived: sum of 3 quarters · filed 2022-03-01 | -$28.61M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$10.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$18.49M derived: sum of 2 quarters · filed 2020-11-05 | -$23.69M 10-Q · filed 2020-11-05 | -$32.55M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-06-30 | -$7.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$12.81M 10-Q · filed 2020-08-05 | -$21.66M derived: sum of 3 quarters · filed 2021-03-11 | -$26.32M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-03-31 | -$5.20M 10-Q · filed 2020-05-07 | -$14.05M derived: sum of 2 quarters · filed 2021-03-11 | -$18.71M derived: sum of 3 quarters · filed 2021-03-11 | |
| 2018-12-31 | -$8.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$13.51M derived: sum of 2 quarters · filed 2021-03-11 | -$26.08M 10-K · filed 2021-03-11 | |
| 2018-09-30 | -$4.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$17.22M 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | -$12.57M 10-Q · filed 2019-08-08 | |||
| 2017-12-31 | -$1.42M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |